Quick Take
Turning Point Therapeutics (TPTX) intends to raise gross proceeds of $100 million from a U.S. IPO, according to an S-1 registration statement.
The firm is developing small molecule, targeted oncology therapies for various cancers.
TPTX is preparing to enter Phase 2 trials for its lead candidate and won’t have initial trial data until the second half of 2020 at the earliest.
Company & Technology
San Diego, California-based Turning Point was founded in 2013 to address what it believed were major limitations of existing cancer therapies and improve patient outcomes through